4- ((9- cyclopentyl- 7,7- difluoro- 5- methyl- 6- oxo- 6,7,8,9- tetrahydro- 5H- pyrimido(4,5- b)(1,4)diazepin- 2- yl)amino)- 2- fluoro- 5- methoxy- N- (1- methylpiperidin- 4- yl)benzamide

a polo-like kinase 1 inhibitor; structure in first source

Also Known As:

TAK-960

Networked: 5 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azepines: 11
    - 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido(4,5-b)(1,4)diazepin-2-yl)amino)-2-fluoro-5-methoxy-N-(1-methylpiperidin-4-yl)benzamide: 5
Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Benzoates: 426
        Aminobenzoates: 1
        para-Aminobenzoates: 43
        4-Aminobenzoic Acid: 437
        4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido(4,5-b)(1,4)diazepin-2-yl)amino)-2-fluoro-5-methoxy-N-(1-methylpiperidin-4-yl)benzamide: 5
- Carboxylic Acids: 973
  - Carbocyclic Acids
    - Benzoates: 426
      - Aminobenzoates: 1
        para-Aminobenzoates: 43
        4-Aminobenzoic Acid: 437
        4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido(4,5-b)(1,4)diazepin-2-yl)amino)-2-fluoro-5-methoxy-N-(1-methylpiperidin-4-yl)benzamide: 5

Experts

1.	Kuida, Keisuke: 2 articles (01/2018 - 03/2012)
2.	Hikami, Kouki: 2 articles (06/2013 - 03/2012)
3.	Hikichi, Yuichi: 2 articles (06/2013 - 03/2012)
4.	Ichikawa, Takashi: 2 articles (06/2013 - 03/2012)
5.	Kawamoto, Tomohiro: 2 articles (06/2013 - 03/2012)
6.	Nie, Zhe: 2 articles (06/2013 - 03/2012)
7.	Uchiyama, Noriko: 2 articles (06/2013 - 03/2012)
8.	Zhang, Lilly: 2 articles (06/2013 - 03/2012)
9.	Arcaroli, John J: 1 article (01/2018)
10.	Bagby, Stacey M: 1 article (01/2018)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2018 - "Fifty-five CRC cell lines and 18 PDX models were exposed to TAK-960 and evaluated for proliferation (IC50) and Tumor Growth Inhibition Index, respectively. " 10/27/2015 - "TAK-960 did not sensitize cancer cells to radiation when an insufficient amount of time was provided to induce mitotic arrest. " 10/27/2015 - "We herein investigated whether PLK1 blockade enhanced the cytotoxic effects of radiation by modulating cell cycle phases of cancer cells using the novel small molecule inhibitor of PLK1, TAK-960. " 06/15/2013 - "TAK-960 is currently undergoing Phase I evaluation in adult patients with advanced solid malignancies." 03/01/2012 - "TAK-960 has entered clinical evaluation in patients with advanced cancers."
2.	Leukemia 03/01/2012 - "Treatment with once daily TAK-960 exhibited significant efficacy against multiple tumor xenografts, including an adriamycin/paclitaxel-resistant xenograft model and a disseminated leukemia model. "
3.	Colorectal Neoplasms (Colorectal Cancer) 03/01/2012 - "In animal models, oral administration of TAK-960 increased pHH3 in a dose-dependent manner and significantly inhibited the growth of HT-29 colorectal cancer xenografts. " 01/01/2018 - "Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer."
4.	Neurofibrosarcoma (MPNST) 01/01/2015 - "These effects were confirmed in vivo, such that TAK-960 more effectively inhibited CHP100 than MPNST xenografts. " 01/01/2015 - "With suppression of Mcl-1 by siRNA, TAK-960 induced apoptosis in MPNST cells as well. "
5.	Sarcoma (Soft Tissue Sarcoma) 01/01/2015 - "All the sarcoma cell lines were sensitive to TAK-960 with IC50s in the low nanomolar range. "

Related Drugs and Biologics

1.	Paclitaxel (Taxol)
2.	Doxorubicin (Adriamycin)
3.	Adenosine Triphosphate (ATP)
4.	Small Interfering RNA (siRNA)
5.	Radiation-Sensitizing Agents
6.	Phosphotransferases (Kinase)

Related Therapies and Procedures

1.	Oral Administration